アジャイル

AGILE — Grokipedia Fact-checked by Grok 4 months ago AGILE Ara Eve Leo Sal 1x Agile is a mindset and iterative approach to project management and software development that emphasizes flexibility, collaboration, and rapid adaptation to change in uncertain environments. [1] It promotes the delivery of value through cross-functional, self-organizing teams that evolve solutions incrementally based on continuous feedback, rather than rigid upfront planning. [1] The foundations of Agile were formalized in 2001 through the Manifesto for Agile Software Development , authored by 17 software practitioners including Kent Beck, Jeff Sutherland, and Ken Schwaber, who sought to address the limitations of traditional, plan-driven methods like Waterfall. [2] This manifesto articulated a shift toward valuing individuals and interactions, working software, customer collaboration, and responding to change over processes, documentation, contracts, and plans. Its roots trace back to earlier methodologies, such as iterative and incremental development practices from the 1960s and 1970s, but the manifesto unified these into a cohesive framework that has since influenced global software practices. [1] At its core, Agile is guided by 12 principles that support sustainable development, including customer satisfaction through early and continuous delivery, welcoming changing requirements, frequent delivery of working software, close daily collaboration between business stakeholders and developers, motivated individuals supported by the work environment, face-to-face conversation as the most efficient communication method, working software as the primary measure of progress, sustainable pace for sponsors, developers, and users, continuous attention to technical excellence and good design, simplicity in maximizing work not done, self-organizing teams, and regular reflection and adjustment. These principles underpin various Agile frameworks, such as Scrum—which structures work into time-boxed sprints with roles like product owner and scrum master—and Kanban, which visualizes workflow to limit work in progress and enhance flow. [1] Originally focused on software development to mitigate risks from complex, evolving requirements, Agile has expanded beyond IT into fields like marketing, education, and organizational management, fostering enterprise-wide agility to navigate volatility. [1] Its adoption has grown significantly; as of 2023, a survey indicated that just over 70% of respondents use Agile practices in their software development life cycle. [3] Background and History Origins and Development The AGILE trial was conceived in early 2020 as a response to the rapidly escalating COVID-19 pandemic, with the goal of establishing a flexible platform to expedite the evaluation of potential treatments. Developed by a team at the University of Liverpool, the trial adopted a seamless phase I/IIa adaptive design to test multiple candidate agents simultaneously, allowing for efficient dose-finding, safety assessment, and efficacy signals in adults with mild to moderate COVID-19. This multi-arm, multi-stage structure was inspired by prior platform trials in oncology and critical care, adapted for infectious diseases to minimize redundancy and accelerate decision-making on promising therapies. The master protocol was crafted to incorporate new candidates via candidate-specific appendices, ensuring consistent methodology while enabling rapid amendments based on emerging data. [4] Initial planning and protocol development occurred in the first half of 2020, leveraging expertise from the Liverpool Centre for Endpoint Analytics Research and the Centre for Experimental Therapeutics. The first participant was enrolled on July 3, 2020, marking the activation of the initial UK sites. By late 2021, the trial had expanded to include international sites, with the first site opening in South Africa in October 2021, reflecting its design for global collaboration to enhance recruitment and diversity. Sites were established in the United Kingdom (e.g., Liverpool, London, Manchester, and Southampton) and South Africa (e.g., Cape Town and Johannesburg), facilitating testing in varied populations and settings. This international footprint was crucial for addressing the pandemic's global scope, with South African sites contributing to evaluations in high-burden areas. [5] [6] [7] Funding for AGILE's inception came from Cancer Research UK core grants, which supported the master protocol, electronic data capture system, randomization tools, and electronic consent processes. In June 2020, Unitaid awarded £2.2 million to launch the platform and test initial candidates, emphasizing its potential to identify "game-changing" drugs for low- and middle-income countries. Additional support followed in February 2021, with £3.2 million from the UK Medical Research Council and National Institute for Health and Care Research (NIHR), enabling expansion of phase IIa efficacy evaluations and integration of more arms. These resources underscored the trial's priority in the UK's COVID-19 research ecosystem, positioning AGILE as the nation's first dedicated phase I/IIa platform for pandemic therapeutics. [4] [8] [9] Leadership was provided by principal investigator Saye Khoo, Professor of Clinical Pharmacology at the University of Liverpool, alongside co-investigators such as Gillian Griffiths (trial statistician), Richard FitzGerald, and Thomas Jaki, who shaped the Bayesian adaptive framework. The team's rationale for the multi-arm platform emphasized resource efficiency during a crisis, reducing the time from lab to phase III by up to 75% compared to traditional trials, while maintaining rigorous safety monitoring. This approach was informed by consultations with regulators, ethicists, and international partners to ensure feasibility and ethical robustness. AGILE's development highlighted the value of pre-existing infrastructure in academic centers for rapid pandemic response. [10] [6] Role in COVID-19 Response The AGILE platform played a pivotal role in the UK's COVID-19 response by providing a dedicated early-phase (I/IIa) evaluation framework for novel therapeutics, addressing critical gaps in the rapid assessment of antivirals and monoclonal antibodies that could prevent disease progression in non-hospitalized patients. [4] Unlike larger phase III trials such as RECOVERY, which focused on hospitalized patients and repurposed drugs like dexamethasone, AGILE emphasized seamless, adaptive testing of new candidates to accelerate their transition to later-stage studies, thereby complementing the broader ecosystem of COVID-19 research. [4] This approach enabled efficient dose-finding and preliminary efficacy signals for agents targeting viral replication or immune modulation early in infection, filling a void left by the initial emphasis on severe cases. [4] AGILE integrated with global initiatives by designing its outputs to inform international efforts, with promising candidates recommended for evaluation in platforms like the WHO's SOLIDARITY trial or the UK's RECOVERY trial. [4] Funded by the UK National Institute for Health Research (NIHR), it expanded internationally to sites in South Africa starting in 2021, with plans for additional sites including Uganda, enhancing access to diverse populations and supporting equitable global pandemic responses. [4] Although primarily UK-led and not directly part of U.S.-centric programs like Operation Warp Speed, AGILE's model aligned with worldwide calls for agile trial designs to expedite therapeutic development during outbreaks. [4] By 2023, AGILE had evaluated at least nine candidate-specific trials (CSTs) involving agents such as molnupiravir, nitazoxanide, and VIR-7832, fast-tracking several for further development and contributing key data on their pharmacokinetics, safety, and virological effects. [11] These efforts yielded influential publications, including phase II results on molnupiravir in The Lancet Infectious Diseases , which demonstrated reduced viral clearance time in early COVID-19 cases, informing subsequent approvals. [12] As of 2024, the trial remains active and recruiting, with potential for adaptation to other emerging infectious diseases. Looking beyond SARS-CoV-2, the platform's adaptive structure positions it for repurposing against other coronaviruses or emerging pandemics, with protocols flexible enough to incorporate new threats post-2022. [4] [5] Objectives and Scope Primary Goals The primary objective of the AGILE trial is to enable the rapid, adaptive evaluation of multiple candidate therapeutics for COVID-19 in a seamless phase Ib/IIa platform, with a focus on determining optimal dosing, safety profiles, and preliminary efficacy signals to accelerate progression to later-phase trials. [5] This is achieved through a Bayesian adaptive design that incorporates candidate-specific trials (CSTs) within a single master protocol, allowing simultaneous assessment of agents like molnupiravir and monoclonal antibodies in adults with confirmed SARS-CoV-2 infection across varying disease severities. [5] The platform prioritizes early-phase testing to identify promising interventions that prevent disease progression, bridging preclinical development to confirmatory studies in platforms such as RECOVERY. [4] Secondary goals include the identification of biomarkers for disease progression and treatment response, such as changes in viral load and time to virological clearance, alongside pharmacokinetic analyses in diverse populations to inform dosing in real-world settings. [5] The trial also aims to demonstrate the platform's scalability, enabling its reuse for evaluating treatments against emerging variants or future outbreaks through flexible amendments to the master protocol and international site expansion. [4] These objectives support comprehensive translational endpoints, including safety monitoring via adverse event rate